Stabilized GHRH analogue — FDA-approved for visceral fat reduction in HIV lipodystrophy.
Trans-3-hexenoic acid modification stabilizes the molecule against enzymatic degradation. Binds GHRH receptors, stimulating GH production. GH then stimulates IGF-1, which reduces visceral adiposity through lipolysis.
Only GHRH analogue with FDA approval (Egrifta). Notable research interest in cognitive function — several studies show improved memory and executive function in older adults at 20mg daily doses.
The cognitive benefits appear separate from the body composition effects, with some researchers specifically studying Tesamorelin for age-related cognitive decline and mild cognitive impairment.